https://doi.org/10.4081/monaldi.2022.2343
Sarcoidosis-like reaction secondary to adalimumab treatment in a patient with axial spondyloarthritis
Submitted: June 1, 2022
Accepted: June 23, 2022
Published: July 4, 2022
Accepted: June 23, 2022
Abstract Views: 979
PDF: 299
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Anti-TNF agents, namely adalimumab, are safe drugs that represent an important arsenal in the treatment of immune-mediated inflammatory diseases. “Paradoxical effects” have been described with their use. A sarcoidosis “like” reaction induced by these agents is rare and is characterized by a systemic granulomatous reaction indistinguishable from sarcoidosis. We present a 55-year-old male patient, with axial spondyloarthritis, treated with with adalimumab. About 17 months under this therapy, he complained of dry cough and wheezing. Chest CT showed a peri-lymphatic and pericisural micronodular pattern and hilo-mediastinal lymph nodes, suggestive of sarcoidosis. Angiotensin converting enzyme was increased. Assuming the hypothesis of a sarcoidosis-like reaction secondary to adalimumab this therapy was discontinued with progressive improvement in the patient's complaints and in the radiological changes.
Bradley J. TNF-mediated inflammatory disease. J Pathol 2008;214:149–60.
DOI: https://doi.org/10.1002/path.2287
Wendling D, Prati C. Paradoxical effects of anti-TNF-α agents in inflammatory diseases. Expert Rev Clin Immunol. 2014;10:159–69.
DOI: https://doi.org/10.1586/1744666X.2014.866038
Bhargava S, Perlman DM, Allen TL, et al. Adalimumab induced pulmonary sarcoid reaction. Respir Med Case Rep 2013;10:53-5.
DOI: https://doi.org/10.1016/j.rmcr.2013.07.002
EMA Europe [Internet]. Humira product information. [cited 2022 Apr 20]. Available from: https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf
Obi ON, Lower EE, Baughman RP. Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. Expert Rev Clin Pharmacol 2021;14:179–210.
DOI: https://doi.org/10.1080/17512433.2021.1878024
Chopra A, Nautiyal A, Kalkanis A, Judson MA. Drug-induced sarcoidosis-like reactions. Chest 2018;154:664–77.
DOI: https://doi.org/10.1016/j.chest.2018.03.056
Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003;361:1111-8.
DOI: https://doi.org/10.1016/S0140-6736(03)12888-7
Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357:2153-65.
DOI: https://doi.org/10.1056/NEJMra071714
Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011;41:256–64.
DOI: https://doi.org/10.1016/j.semarthrit.2010.11.002
Decock A, Van Assche G, Vermeire S, et al. Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy? J Crohns Colitis 2017;11:378-83.
DOI: https://doi.org/10.1093/ecco-jcc/jjw155
Khasnis AA, Calabrese LH. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum 2010;40:147-63.
DOI: https://doi.org/10.1016/j.semarthrit.2009.09.001
How to Cite
Gonçalves Pimenta, Diana Alexandra, Leonor Meira, Rui Rolo, and Lurdes Ferreira. 2022. “Sarcoidosis-Like Reaction Secondary to Adalimumab Treatment in a Patient With Axial Spondyloarthritis”. Monaldi Archives for Chest Disease 93 (1). https://doi.org/10.4081/monaldi.2022.2343.
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Sumita P. Agrawal, Pranav Ish, Akhil Dhanesh Goel, Nitesh Gupta, Shibdas Chakrabarti, Dipak Bhattacharya, Manas Kamal Sen, Jagdish Chander Suri, Diagnostic utility of endobronchial ultrasound features in differentiating malignant and benign lymph nodes , Monaldi Archives for Chest Disease: Vol. 88 No. 2 (2018)
- Hazuki Fujimoto, Yohei Kanzawa, Hidemine Senba, Tetsuo Washio, Yukiko Kato, Kei Kawano, Shimpei Mizuki, Jun Ohnishi, Takahiro Nakajima, Naoto Ishimaru, Saori Kinami, Hemophagocytic syndrome in a patient with long-term stable pulmonary sarcoidosis with progressive spleen and bone marrow lesion , Monaldi Archives for Chest Disease: Vol. 93 No. 4 (2023)
- Amarendra Kumar Shukla, Amrutha Peter, Jitendra Kishore Bhargava, Veerendra Arya, Manish Kumar Gupta, Nishtha Yadav, Pawan Tiwari, Sarcoidosis presenting as bilateral optic neuritis after ChAdOx1 nCoV-19 vaccination , Monaldi Archives for Chest Disease: Vol. 93 No. 1 (2023)
- Mamta Singh, Kunal Deokar, Bibhuti Prassan Sinha, Monika Keena, Govind Desai, Ocular manifestations of common pulmonary diseases: a narrative review , Monaldi Archives for Chest Disease: Vol. 94 No. 1 (2024)
- R. Carbone, A. Douroukas, V. Arena, D. Cantalupi, E. Balleari, R. Ghio, E. Pelosi, Does 18F-fluorodeoxyglucose PET/CT have a role in the management of pulmonary and extra pulmonary sarcoidosis? , Monaldi Archives for Chest Disease: Vol. 69 No. 2 (2008): Pulmonary series
- M. Majori, M. Anghinolfi, A. Scarascia, L. Gnetti, A. Pavarani, A. Casalini, Pulmonary sarcoidosis mimicking multiple pulmonary metastases , Monaldi Archives for Chest Disease: Vol. 77 No. 1 (2012): Pulmonary series
- Alessandro Mezzani, Francesco Cacciatore, Raffaella Catanzaro, Alessandra Gualco, Daniela Guzzetti, Dario Leosco, Mauro Monelli, Franco Tarro Genta, Paolo Totaro, Egidio Traversi, Emanuela Zanelli, Pantaleo Giannuzzi, A multicenter, randomized, controlled trial on short-term feasibility and impact on functional capacity, symptoms and neurohumoral activation , Monaldi Archives for Chest Disease: Vol. 82 No. 1 (2014): Cardiac series
- Neeta Singla, Amitesh Gupta, U.K. Khalid, Ravindra Kumar Dewan, Rupak Singla, Clinical profile, risk factors, disease severity, and outcome for COVID-19 disease in patients with tuberculosis on treatment under the National Tuberculosis Elimination Program: a cohort of 1400 patients , Monaldi Archives for Chest Disease: Early Access
- Andrea Salzano, Domenico Sirico, Michele Arcopinto, Alberto Maria Marra, Germano Guerra, Aldo Rocca, Alessandra Grieco, Francesco Giallauria, Carlo Vigorito, Anti remodeling therapy: new strategies and future perspective in post-ischemic heart failure. Part II , Monaldi Archives for Chest Disease: Vol. 82 No. 4 (2014): Cardiac series
- Domenico Sirico, Andrea Salzano, Dario Celentani, Michele Arcopinto, Alberto Maria Marra, Emanuele Bobbio, Angelo Russo, Francesco Giallauria, Carlo Vigorito, Anti remodeling therapy: new strategies and future perspective in post-ischemic heart failure: Part I , Monaldi Archives for Chest Disease: Vol. 82 No. 4 (2014): Cardiac series
You may also start an advanced similarity search for this article.
